Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.47 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 5/20 | 0.47 |
| ▸ | CTSK | P43235 | 5/20 | 0.47 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.42 |
| ▸ | ITGAV | P06756 | 2/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.42 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3314540 | 0.93 | CTSS (0.45) | PTPN1ITGA4ITGB7CTSSCTSK | |
| SCHEMBL4625765 | 0.92 | PTPN1 (0.52) | PTPN1ITGA4ITGB7CTSSCTSK | |
| SCHEMBL4627526 | 0.88 | ITGB1 (0.52) | PTPN1ITGA4ITGB7CTSSCTSK | |
| SCHEMBL4624438 | 0.88 | PTPN1 (0.54) | PTPN1ITGA4ITGB7CTSSCTSK | |
| SCHEMBL4627618 | 0.86 | PTPN1 (0.58) | PTPN1CTSSCTSKCTSBACE | |
| SCHEMBL3315927 | 0.85 | ITGB1 (0.55) | PTPN1ITGA4ITGB7CTSSCTSK | |
| SCHEMBL4627669 | 0.85 | ITGB1 (0.55) | PTPN1ITGA4ITGB7CTSSCTSK | |
| SCHEMBL3314031 | 0.85 | ITGB1 (0.55) | PTPN1ITGA4ITGB7CTSSCTSK | |
| SCHEMBL3314491 | 0.85 | CTSS (0.48) | PTPN1ITGA4ITGB7CTSSCTSK | |
| SCHEMBL4624246 | 0.83 | ITGB1 (0.64) | ITGA4ITGB7ITGB1ITGAVITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200095698-A1 | ELECTROLYTIC TIN PLATING SOLUTION | C. UYEMURA & CO., LTD. (JP) | 2020-03-26 | — | — | US | claimed |
| EP-1432388-B1 | AGENT FOR COLOURING FIBRES CONTAINING KERATIN | HENKEL AG & CO KGAA (DE) | 2008-06-18 | — | — | EP | claimed |
| EP-1501801-B1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF VLA-4 DEPENDENT DISEASES | UCB PHARMA SA (BE) | 2008-01-23 | — | — | EP | claimed |
| EP-1432428-B1 | Agent for colouring fibres containing keratin | HENKEL KGAA (DE) | 2006-11-02 | — | — | EP | claimed |
| US-20050262647-A1 | Agent for dyeing fibers containing keratin | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 2005-12-01 | — | — | US | claimed |
| US-20200095698-A1 | ELECTROLYTIC TIN PLATING SOLUTION | C. UYEMURA & CO., LTD. (JP) | 2020-03-26 | — | — | US | disclosed |
| US-20050262647-A1 | Agent for dyeing fibers containing keratin | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 2005-12-01 | — | — | US | disclosed |
| WO-1998041520-A1 | A PROCESS FOR THE PREPARATION OF FURAZIDIN | ADAMED SP. Z O.O. (PL) | 1998-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050262647-A1 | Agent for dyeing fibers containing keratin | KRT18, CKAP4, KRTCAP2 | PTPN1 4644/4885ITGA4 2180/4885ITGB7 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.